Meeting the societal need for new antibiotics: The challenges for the pharmaceutical industry

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 168-172

  O'Brien, Seamus ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM IDENTIFICATION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CLINICAL TRIAL (TOPIC); DRUG BIOAVAILABILITY; DRUG COST; DRUG DESIGN; DRUG INDUSTRY; DRUG SCREENING; HEALTH CARE NEED; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REIMBURSEMENT; DRUG DEVELOPMENT; HUMAN; MULTIDRUG RESISTANCE; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; PROCEDURES;

ANTI-BACTERIAL AGENTS; DRUG DESIGN; DRUG DISCOVERY; DRUG INDUSTRY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MODELS, ORGANIZATIONAL;

EID: 84941072573     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12401     Document Type: Article

References (13)

1. Laxminarayan R, Duse A, Wattal C, Zaidi AKM, Wertheim HFL, Sumpradit N, Vlieghe E, Hara GL, Gould IM, Goossens H, Greko C, So AD, Bigdeli MB, Tomson G, Woodhouse W, Ombaka E, Peralta AQ, Qamar FN, Mir F, Kariuki S, Bhutta ZA, Coates A, Bergstrom R, Wright GD, Brown ED, Cars O,. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013; 13: 1057-1098.
2. Edelstein MV, Skleenova EN, Shevchenko OV, D'Souza JW, Tapalski DV, Azizov IS, Sukhorukova MV, Pavlukov RA, Toleman MA, Walsh TR,. Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect Dis 2013; 13: 867-887.
3. Silvia Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP,. Clinical epidemiology of the global expansion of Klebsiella pneumonia carbapenemases. Lancet Infect Dis 2013; 13: 785-796.
4. Lewis K,. Platforms for antibiotic discovery. Nat Rev Drug Discov 2013; 12: 371-387.
5. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ,. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
6. Craig WA,. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
7. Ambrose PG, Bhavnani SM, Rubino CM, Louie A, Gumbo T, Forrest A, Drusano G,. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007; 44: 79-86.
8. Glasner C, Albiger B, Buist G, Andrasevic AT, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poires L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Donker T, Monnet DL, Grundmann H,. Carbapenemase-producing Enterobacteriaceae in Europe: a survey among 39 national experts from 39 countries. Euro Surveill 2013; 18: 1-7.
9. Rex JH, Eisenstein B, Adler J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, Lancaster C, Jackson J,. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 2013; 13: 269-276.
10. Guidance for Industry. Antibacterial therapies for patients with unmet medical need for treatment of serious bacterial diseases. 2013. Available at http://www.fda.gov/downloads.Drugs/guidancecomplianceregulatoryinformation/guidances/UCM359184.pdf (last accessed 24 May 2014).
11. European Medicines Agency. Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections. 2013. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/11/WC500153953.pdf (last accessed 24 May 2014).
12. Spellberg B, Sharma P, Rex JH,. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nat Rev Drug Discov 2012; 11: 168-170.
13. Brown ED,. Is the GAIN Act a turning point in new antibiotic discovery. Can J Microbiol 2013; 59: 153-156.